Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by NorthRock Partners LLC

NorthRock Partners LLC increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 32.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 4,458 shares of the medical research company's stock after purchasing an additional 1,093 shares during the quarter. NorthRock Partners LLC's holdings in Thermo Fisher Scientific were worth $2,319,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Stonegate Investment Group LLC grew its position in Thermo Fisher Scientific by 0.3% in the 4th quarter. Stonegate Investment Group LLC now owns 6,788 shares of the medical research company's stock valued at $3,531,000 after acquiring an additional 18 shares during the last quarter. Semus Wealth Partners LLC grew its position in Thermo Fisher Scientific by 4.0% in the 4th quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock valued at $245,000 after acquiring an additional 18 shares during the last quarter. Eagle Rock Investment Company LLC grew its position in Thermo Fisher Scientific by 0.3% in the 4th quarter. Eagle Rock Investment Company LLC now owns 7,463 shares of the medical research company's stock valued at $3,882,000 after acquiring an additional 19 shares during the last quarter. KRS Capital Management LLC grew its position in Thermo Fisher Scientific by 1.5% in the 4th quarter. KRS Capital Management LLC now owns 1,317 shares of the medical research company's stock valued at $685,000 after acquiring an additional 20 shares during the last quarter. Finally, Evernest Financial Advisors LLC grew its position in Thermo Fisher Scientific by 4.0% in the 4th quarter. Evernest Financial Advisors LLC now owns 521 shares of the medical research company's stock valued at $271,000 after acquiring an additional 20 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

TMO has been the topic of several research analyst reports. Robert W. Baird cut their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Royal Bank of Canada lowered their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Argus lowered their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a report on Tuesday, April 29th. The Goldman Sachs Group set a $610.00 target price on Thermo Fisher Scientific and gave the stock a "buy" rating in a report on Wednesday, April 23rd. Finally, Raymond James reiterated an "outperform" rating and issued a $667.00 target price (up from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $607.43.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the transaction, the senior vice president now directly owns 10,816 shares of the company's stock, valued at approximately $5,759,736.32. This represents a 25.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the transaction, the chief executive officer now directly owns 115,174 shares in the company, valued at $59,506,950.58. This represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 14,075 shares of company stock worth $7,305,942. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Up 1.8%

Thermo Fisher Scientific stock traded up $7.22 during midday trading on Friday, reaching $412.15. The company's stock had a trading volume of 2,498,185 shares, compared to its average volume of 1,839,114. The stock's 50-day simple moving average is $453.88 and its 200-day simple moving average is $510.42. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a 52-week low of $390.50 and a 52-week high of $627.88. The stock has a market capitalization of $155.58 billion, a P/E ratio of 24.93, a PEG ratio of 2.99 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. During the same period last year, the business posted $5.11 earnings per share. The firm's revenue was up .2% compared to the same quarter last year. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, March 14th. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a yield of 0.42%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.